MONTEMURRO, FILIPPO
 Distribuzione geografica
Continente #
EU - Europa 124
Totale 124
Nazione #
IT - Italia 124
Totale 124
Città #
Genoa 93
Rapallo 17
Genova 11
Bordighera 3
Totale 124
Nome #
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer, file be0f987c-8f2d-4180-9b26-7f155395729e 112
Patterns of Care and Clinical Outcomes of HER2-positive Metastatic Breast Cancer Patients With Newly Diagnosed Stage IV or Recurrent Disease Undergoing First-line Trastuzumab-based Therapy: A Multicenter Retrospective Cohort Study, file e268c4c8-5c00-a6b7-e053-3a05fe0adea1 3
Dose-dense adjuvant chemotherapy in premenopausal breast cancer patients: A pooled analysis of the MIG1 and GIM2 phase III studies, file e268c4c8-57c1-a6b7-e053-3a05fe0adea1 2
Endocrine therapy in premenopausal women with breast cancer: a critical appraisal of current evidence, file e268c4c8-8ea0-a6b7-e053-3a05fe0adea1 2
Trastuzumab-related cardiotoxicity in patients with nonlimiting cardiac comorbidity, file e268c4c9-c7be-a6b7-e053-3a05fe0adea1 2
Impact of body mass index on the clinical outcomes of patients with HER2-positive metastatic breast cancer, file e268c4c8-5c6d-a6b7-e053-3a05fe0adea1 1
Controversies in monitoring metastatic breast cancer during systemic treatment. Results of a GIM (Gruppo Italiano Mammella) survey, file e268c4c9-08c0-a6b7-e053-3a05fe0adea1 1
Endocrine therapy for hormone receptor-positive, HER2-negative metastatic breast cancer: Extending endocrine sensitivity, file e268c4cc-13e2-a6b7-e053-3a05fe0adea1 1
Totale 124
Categoria #
all - tutte 164
article - articoli 164
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 328


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20206 1 0 0 0 2 2 1 0 0 0 0 0
2020/20211 0 0 0 1 0 0 0 0 0 0 0 0
2022/202330 0 0 0 0 0 0 0 1 7 7 7 8
2023/202483 7 4 24 10 10 6 12 10 0 0 0 0
Totale 124